Home / Intelligence / White Papers / 2022 NRDL Pricing Implementation and Access Outcomes in China
The pricing and market access (P&MA) landscape in China has been rapidly evolving as the country continuously attempts to balance rewarding innovation and sustainability of healthcare funding. China represents a unique and dynamic market archetype for manufacturers especially in terms of P&MA strategies.
China’s aging population (≥60 years) is estimated to exceed 400 million by 2035 driving a significant rise in government healthcare expenditure and medical insurance subsidies in the future. As such, the Chinese government has acknowledged the important role of multi-national companies to drive innovation as seen in the Healthy China 2030 policy and an increase in the National Reimbursement Drug List (NRDL) negotiation success rate for international branded drugs.
Since the first NRDL negotiation back in 2017, the NRDL has maintained an important presence in China’s market access pathway, providing broad coverage and significant market uptake opportunities for listed products. In the last 5 years, the NRDL has been updated annually with a notable > 75% reduction in the time taken between reimbursement and regulatory approval for innovative therapies.
With the intention to strive for equitable access across regions and increase single-payer negotiation power, payers in China have removed the provincial autonomy to adjust the reimbursement drug list and consolidated to one unified public reimbursement pathway. Therefore, staying informed on the NRDL changes is more critical than ever. The 2022 NRDL update represented the sixth consecutive year of negotiation, with five key significant updates observed; all updates intended to facilitate an optimized review process.
Complete the form below to access the full white paper
By submitting this form, creating an account, and/or using our website (or using our Services) you agree to our Privacy Policy. Information provided by you is stored in our database and may be used for sending you additional information about Trinity (including Trinity’s partners and affiliates) and our products and services. Such information may be transferred for this purpose to Trinity and affiliates in other countries. If you would like to opt out in the future, please email _compliance@trinitylifesciences.com.
Related Intelligence
Blog
Early China Launch of PIASKY® in the Fight Against PNH
In February 2024, the National Medical Products Administration (NMPA), China’s drug regulator, granted priority review approval to Roche’s PIASKY (crovalimab), an injectable C5 inhibitor for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). PNH is a rare genetic blood disorder in which the patient’s immune system attacks and destroys red blood cells and platelets. As the […]
Read More
Blog
Rise with the Waves: UK – Now and Beyond – Four Policy Trends That May Shape Pharma’s Future
Executive Summary The global payer landscape is rapidly evolving and is expected to continuously impact manufacturers’ decisions about new launches, portfolio management, trial design and importantly, pricing and market access strategy. In the UK, several policy reforms have been introduced which are expected to improve patient access while balancing financial healthcare sustainability and overall market […]
Read More
Blog
Japan Pricing Policy Reform 2024
Executive Summary The Central Social Insurance Medical Council, the key Japanese reimbursement policy panel known as Chuikyo, introduced the 2024 drug pricing reform in April 2024. Some key features of the reform plan include: The reform outlines a suite of measures aimed at driving innovation while also addressing drug lags (delay in manufacturers launching drugs in Japan […]
Read More